SML1409
Madrasin
≥98% (HPLC)
别名:
2-[（（7-甲氧基-4-甲基-2-喹唑啉基）氨基] -5,6-二甲基-4（1H）-嘧啶酮（9CI）, 2-（7-甲氧基-4-甲基-喹唑啉-2-基氨基）-5,6-二甲基-3H-嘧啶-4-酮, 4（1H）-嘧啶酮，2-[（（7-甲氧基-4-甲基-2-喹唑啉基）氨基] -5,6-二甲基-（9CI）, 4（3H）-嘧啶酮，2-[（（7-甲氧基-4-甲基-2-喹唑啉基）氨基] -5,6-二甲基-, DDD00107587, RNA剪接抑制剂
登录查看公司和协议定价
所有图片(1)
About This Item
经验公式（希尔记法）:
C16H17N5O2
CAS号:
分子量:
311.34
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
推荐产品
![地高辛-11-dUTP，碱性不稳定 =85% (HPLC), solution, pkg of 25 μL (11573152910 [1 mM]), pkg of 125 μL (11573179910 [1 mM]]])](/deepweb/assets/sigmaaldrich/product/images/352/091/ef743cea-ccd8-44f1-8f3b-dec5a1e4f5d1/640/ef743cea-ccd8-44f1-8f3b-dec5a1e4f5d1.jpg)
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
, white to dark brown
溶解性
DMSO: 0.5 mg/mL, clear (warmed)
储存温度
2-8°C
SMILES字符串
CC1=NC(NC(NC(C)=C2C)=NC2=O)=NC3=CC(OC)=CC=C31
InChI
1S/C16H17N5O2/c1-8-9(2)17-16(20-14(8)22)21-15-18-10(3)12-6-5-11(23-4)7-13(12)19-15/h5-7H,1-4H3,(H2,17,18,19,20,21,22)
InChI key
QQJIYKXTEMDJFM-UHFFFAOYSA-N
应用
Madrasin已作为剪接体抑制剂，抑制3T3-L1细胞中前体RNA的剪接加工。
生化/生理作用
Madrasin 是一种高效的、细胞渗透性剪接抑制剂。
Madrasin 是一种高效的、细胞渗透性剪接抑制剂，可干扰剪接体组装的早期阶段。 Madrasin 使 A 复合体的剪接体装配停滞。
Madrasin在较高浓度下具有细胞毒性。在极低浓度下，Madrasin可诱导蛋白亚细胞核定位和引起细胞周期停滞。
警示用语：
Warning
危险声明
危险分类
Acute Tox. 4 Oral
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Yves Mugabo et al.
The Journal of biological chemistry, 293(18), 6736-6750 (2018-03-14)
Adipogenesis involves a complex signaling network requiring strict temporal and spatial organization of effector molecules. Molecular scaffolds, such as 14-3-3 proteins, facilitate such organization, and we have previously identified 14-3-3ζ as an essential scaffold in adipocyte differentiation. The interactome of
Andrea Pawellek et al.
The Journal of biological chemistry, 289(50), 34683-34698 (2014-10-05)
Eukaryotic pre-mRNA splicing is an essential step in gene expression for all genes that contain introns. In contrast to transcription and translation, few well characterized chemical inhibitors are available with which to dissect the splicing process, particularly in cells. Therefore
Andrey A Parkhitko et al.
PLoS genetics, 17(2), e1009354-e1009354 (2021-02-17)
The RB1 tumor suppressor is recurrently mutated in a variety of cancers including retinoblastomas, small cell lung cancers, triple-negative breast cancers, prostate cancers, and osteosarcomas. Finding new synthetic lethal (SL) interactions with RB1 could lead to new approaches to treating
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门